Generated by AI
Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors, with a particular emphasis on ocular cancers. Its lead program centers on belzupacap sarotalocan, a virus-like drug conjugate designed to selectively target cancer cells while preserving healthy tissue and organ function. The company’s platform is built around virus-like particles that deliver therapeutic payloads directly to tumors and support an immune response against cancer. Aura Biosciences is advancing its oncology pipeline across ocular oncology and other related indications, including bladder cancer, using a targeted approach intended for specialist treatment settings. Headquartered in Boston, Massachusetts, Aura Biosciences plays a focused role in the biotechnology market as a developer of novel cancer therapies for hard-to-treat solid tumors.
Website80 Guest Street
Boston, MA, 02135
United States
The latest articles about AURA.
Oxford Biomedica plc (LSE:OXB) confirmed a manufacturing and supply partnership with Aura Biosciences (NASDAQ:AURA) to support Phase 3 development and preparations for potential commercial production of an experimental treatment for ocular cancers. The agreement, established earlier in 2026, covers development and manufacturing activities for Aura’s lead virus-like drug conjugate (VDC) candidate, belzupacap sarotalocan (bel-sar).
Summary of May 9's posts. Generated by AI.
No summary yet.
No summary yet.
Summary of Nov 10's posts. Generated by AI.
Summary of Jun 16's posts. Generated by AI.
Investors talking about AURA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.